Loading
Extracellular Vesicles in Disease / CAR-T Cell Therapy Research / CRISPR and Genetic Engineering · Journal article
Applied Microbiology and Biotechnology · August 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an early-stage in vitro study demonstrating that small extracellular vesicles can be engineered to deliver CRISPR/Cas9 plasmids targeting PD-1 into T cells and that successful knockout enhances T cell cytotoxicity and cytokine release on laboratory assays. The work is mechanistic and proof-of-concept; it lacks animal models, comparative efficacy data, and any clinical translation pathway.
Uncontrolled in vitro experimental study. T cells (in vitro); specific source, donor number, and culture conditions not described.. Intervention: Targeted small extracellular vesicles loaded with CRISPR/Cas9 plasmids targeting PD-1. Compared with: Non-targeted s-EVs and untreated T cells.
Targeted s-EVs exhibited higher uptake by T cells compared to non-targeted s-EVs PD-1 knockout in T cells significantly enhanced cytotoxicity (measured by CFSE staining) compared to untreated T cells PD-1 knockout in T cells significantly enhanced cytokine release (measured by ELISA) compared to untreated T cells
No in vivo efficacy, toxicity, or off-target editing data. PD-1 knockout in T cells significantly enhanced cytotoxicity (measured by CFSE staining) compared to untreated T cells
This approach is not yet clinically applicable. The work establishes a potential platform for T cell engineering but requires validation in animal models and demonstration of safety and efficacy before clinical consideration.
First-in-kind proof-of-concept study demonstrating a novel delivery mechanism in vitro; no animal or clinical data, no comparative efficacy trial, and no hard clinical endpoints reported.
As stated by the source record.
This approach is not yet clinically applicable. The work establishes a potential platform for T cell engineering but requires validation in animal models and demonstration of safety and efficacy before clinical consideration.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Among the emerging cancer therapies, immunotherapy using T cell engineering stands out as one of the most promising approaches. While the clustered regularly interspaced palindromic repeats (CRISPR/Cas) system is widely recognized as one of the most common gene-editing system tools, the main challenge for in vivo delivery applications remains the lack of an efficient and safe intracellular carrier. Small extracellular vesicles (s-EVs), as natural nanoparticles with low immunogenicity, emerge as a promising candidate for delivering the CRISPR/Cas system. Two guide RNAs (gRNAs) targeting the programmed cell death (PD-1) gene were cloned into the PX-459 vector, and these CRISPR/Cas9 plasmids were loaded into targeted s-EVs by electroporation. Subsequently, T cells were exposed to these s-EVs, and the disruption to the PD-1 gene was examined using flow cytometry and sequencing. Flow cytometry results indicated that newly produced targeted s-EVs exhibited a higher uptake by T cells compared to non-targeted s-EVs. The successful loading of PX-459 plasmids into targeted s-EVs and their functional delivery to T cells were confirmed. Subsequent carboxyfluorescein succinimidyl ester (CFSE) staining and enzyme-linked immunosorbent assay (ELISA) analyses demonstrated that the knockout (KO) of the PD-1 gene in T cells significantly enhanced both their cytotoxicity and cytokine release compared to untreated T cells. Targeted s-EVs were used in the current study as a means to deliver the CRISPR/Cas9 system into T cells, enabling genetic modification of target cells. This approach holds the potential to improve and simplify immunotherapy. This study demonstrates a novel approach to genetic modification in T cells using targeted s-EVs containing the CRISPR/Cas9 gene-editing system. Key points •CRISPR/Cas9 is a kind of powerful gene editing system in cancer therapeutics. •s-EVs can be applied as a biological carrier for CRISPR/Cas9 system. • T cell engineering-based immunotherapy is a promising form of anticancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.